Curis Announces Abstracts for Its Partnered Programs, Erivedge(R) and Debio 0932 to be Presented at the 2014 ASCO Annual Meeting

        Print
| Source: Curis, Inc.

LEXINGTON, Mass., May 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that its collaborators, Roche/Genentech and Debiopharm Group™ will present results from clinical studies of Erivedge® and Debio 0932, respectively, at the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) to be held from May 30th to June 3rd in Chicago, IL.

Curis' collaborator, Roche/Genentech will present the following abstracts for Erivedge®, a first-in-class hedgehog pathway inhibitor approved for the treatments of advanced basal cell carcinoma (BCC).

Erivedge Presentations:
Date/Time: Saturday, May 31, 2014, 8:00 AM - 11:45 AM
Abstract #: 9081
Presentation Title: Vismodegib for advanced basal cell carcinoma: duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression.
Presenter: Aleksandar Sekulic, MD, PhD
   
Date/Time:  Saturday, May 31, 2014, 8:00 AM - 11:45 AM
Abstract #: TPS9104
Presentation Title: A phase II study to assess vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma (laBCC): The Vismodegib Neoadjuvant (VISMONEO) study.
Presenter: Laurent Mortier, MD, PhD
   
Date/Time:  Saturday, May 31, 2014, 8:00 AM - 11:45 AM
Abstract #: TPS9116^
Presentation Title: A phase II, single-armed, multicenter trial of neoadjuvant vismodegib in patients with large and/or recurrent basal cell carcinoma: NICCI. 
Presenter: Ulrike Leiter, MD
   
Date/Time:  Saturday, May 31, 2014, 8:00 AM - 11:45 AM
Abstract #: TPS9121
Presentation Title: MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas.
Presenter: Rainer Kunstfeld
   
Date/Time:  Monday, June 2, 2014, 8:00 AM - 11:00 AM
Abstract #: 9012
Presentation Title: Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
Presenter: Karl D. Lewis, MD
   
Date/Time:  Monday, June 2, 2014, 8:00 AM - 11:00 AM
Abstract #: 9013
Presentation Title: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study.
Presenter: Aleksandar Sekulic, MD, PhD

Curis' licensee, Debiopharm will present the following abstracts for Debio 0932, an oral HSP90 inhibitor being investigated in clinical trials for non-small cell lung cancer and renal cell carcinoma.

Debio 0932 Presentations:
Date/Time:  Sunday, June 1, 2014, 8:00 AM - 11:45 AM
Abstract #: 2550^
Presentation Title: Final results from the phase I study expansion cohort of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors. 
Presenter: Pierre Fumoleau, MD
   
Date/Time:  Sunday, June 1, 2014, 8:00 AM - 11:45 AM
Abstract #: TPS2632^
Presentation Title: The HALO study: A phase I-II of the oral HSP90 inhibitor Debio 0932 in combination with SOC in first- and second-line therapy of advanced NSCLC.
Presenter: Jesus Corral Jaime, MD

Additional information on the presentations can be found below and abstracts can be accessed at www.asco.org.

About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers. Curis is seeking to further the development of its pipeline of proprietary targeted cancer drug candidates, including CUDC-907, a dual HDAC and PI3K inhibitor and CUDC-427, a small molecule antagonist of IAP proteins. Erivedge® is our most advanced asset and the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech.  Curis-discovered HSP90 inhibitor, Debio 0932, is being studied in patients with advanced lung and kidney cancers by its partner Debiopharm. For more information, visit Curis' website at www.curis.com.
 

For More Information:
Mani Mohindru, Ph.D.
Vice President, Corporate Strategy and Investor Relations
Curis, Inc.
617-503-6605


Michael P. Gray
Chief Financial and Chief Business Officer
Curis, Inc.
617-503-6632